Sanofi Confident Of 'Tortoise And Hare' COVID-19 Vaccine Strategy
Fast and furious and slow and steady may both be winning strategies in the race to protect the populace from COVID-19, said Sanofi’s Paul Hudson and John Reed, as the firm accelerated the timeline for its recombinant protein-based vaccine in development with GSK.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.
Sanofi's R&D operation has shaken the dust of diabetes off its feet with an update on its ambitious pipeline plans at an R&D day event.
Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.